Cortagen vs Cartalax: which Khavinson peptide fits your goal

I get some version of this question in my inbox at least once a week: "Rick, I found Cortagen and Cartalax on the same vendor page, they look almost identical, which one do I actually need?" Short answer: Cortagen is a cognition peptide aimed at cortical neurons with real (if messy) human clinical data behind it, and Cartalax is a connective-tissue and longevity peptide aimed at fibroblasts with no human data at all, so the "vs" in cortagen vs cartalax is really a "for what" question more than a head-to-head.

Both come out of the same Russian research program, the Khavinson school out of St. Petersburg, and that's exactly why people mix them up. Same lab lineage, similar tiny peptide sequences, similar packaging on gray-market vendor sites. But the tissue targets, the evidence quality, and the cost of getting it wrong are not remotely the same.

What each one is actually built to do

Cortagen is a tetrapeptide (Ala-Glu-Asp-Pro) that the Khavinson framework claims binds DNA promoter regions in cortical neurons specifically. The mechanism, if you buy the underlying theory, is slow: gene-expression changes that build over a 10 to 20 day cycle and are claimed to persist two to three months after you stop. It's a cognition and neuroprotection play, built around that slow gene-expression timeline rather than the fast onset you'd get from semax or selank.

Cartalax is a tripeptide (Ala-Glu-Asp), one amino acid shorter, and it targets fibroblasts, the cells that build and maintain connective tissue broadly, plus kidney cells in one of the three papers behind it. It's positioned as a maintenance and longevity compound for aging connective tissue. If you're dealing with a fresh joint injury, BPC-157 and TB-500 have a far stronger evidence base and clinical track record for that job, and Cartalax isn't trying to compete there.

Evidence quality is where these two actually diverge

This is the part people skip past, and it's the part that should drive the decision. Cortagen has Russian post-stroke clinical data in humans showing cognitive improvement, on top of the rodent Morris water maze and hippocampal BDNF work. That human data is unblinded and wouldn't pass a Western RCT reviewer. It still counts for something, and it's more than Cartalax currently has.

Cartalax has no human data and no animal-in-vivo data at all. What it has is three in-vitro papers from the same Khavinson group. One ran the peptide on aging rat skin fibroblasts and tracked proliferation and breakdown markers, including suppression of MMP-9, the enzyme that chews through collagen and ramps up with age. A second, higher-confidence paper ran it on human skin fibroblasts and found it activated SIRT-1 and SIRT-6 (genome-maintenance and longevity-linked enzymes) and stimulated collagen I synthesis. A third looked at kidney cell culture and found reduced senescence markers alongside increased SIRT-6 expression. A separate review names AED (Cartalax) among the peptides claimed to slow apoptosis and normalize connective-tissue matrix function, though that's a summary of the same underlying lab's work rather than independent confirmation.

That's a real, internally consistent set of lab signals. It is not clinical proof, and I'd be doing you a disservice to pretend three in-vitro papers from one research group answer the question of whether Cartalax does anything meaningful in a living person's joints.

Cost and side-effect load

Neither peptide carries a heavy side-effect profile in what's been reported. Cortagen shows infrequent injection-site reactions and occasional mild headache early in a cycle, with no serious adverse events documented at standard doses in the Russian literature. Cartalax reports are similarly mild, mostly injection-site redness and transient swelling, though the safety data for both stops well short of anything a Western pharmacovigilance system would call complete.

Cost tends to track with dose size, and this is where Cartalax gets genuinely confusing. The Khavinson-school protocol runs 5 to 10 micrograms a day; the peptide-community convention that's actually circulating runs about 2 milligrams a day, roughly 200 to 400 times higher, and there's no dose-finding study to say which is right. Cortagen's dosing is comparatively coherent: 200 to 400 mcg subcutaneously for a 10 to 20 day cognitive cycle, run two to three times a year, with a separate higher-dose IM protocol reserved for the post-stroke clinical context.

I try to stay evidence-based with peptides, and Cartalax's dosing gap is unusual even among Khavinson-family compounds, most of which agree reasonably well between school and community. That gap alone changes what "cost" means: at community dosing, you're running through vials faster and at a higher per-cycle spend than the Khavinson literature would suggest is even necessary.

Now the part my lawyer makes me say, and he's right: the doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Who each one actually suits

If you're chasing cognitive support, especially recovery-adjacent cognitive support, and you're comfortable running a compound whose best evidence is unblinded Russian clinical data plus solid rodent mechanism work, Cortagen is the one built for that job. If you want same-week effects, semax or selank are the better-studied, faster-acting comparison.

If your interest is long-term connective-tissue maintenance and cellular aging, sitting alongside training, protein intake, and sleep rather than replacing any of them, Cartalax fits that maintenance lane once the fundamentals are already in place. It is not the peptide for a fresh sprain or a torn ligament; that's still BPC-157 and TB-500 territory, where the clinical track record is genuinely stronger.

One line that applies to both: anyone with active or historical cancer should treat Cartalax as off the table entirely, since its proposed mechanism suppresses p53, one of the body's main brakes on runaway cell division. I see this question come up in practitioner circles more than you'd expect, and it's not a gray area.

And on sourcing, both compounds sit in the part of the peptide market with the highest counterfeiting rates I've seen flagged, Khavinson-family peptides specifically. A third-party Certificate of Analysis confirming identity and purity above 99 percent isn't optional here. I check for it before I'll trust any vendor with a compound in this family, and you should too.

If you're building out a broader peptide protocol and want to see how a maintenance compound like this fits next to more acute tools, our fat-loss stacking piece walks through the same layering logic even though the compounds are different.